Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
- Registration Number
- NCT02669771
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1018
Inclusion Criteria
- no history of treatment with enzalutamide
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Enzalutamide group enzalutamide oral
- Primary Outcome Measures
Name Time Method Incidences of Adverse Events Up to 2 years
- Secondary Outcome Measures
Name Time Method Change from baseline in PSA value Up to 2 years PSA: prostate-specific antigen
Overall Survival Up to 2 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of enzalutamide in castration-resistant prostate cancer (CRPC)?
How does enzalutamide compare to other androgen receptor inhibitors in CRPC treatment outcomes?
Which biomarkers are associated with enzalutamide response in castration-resistant prostate cancer patients?
What are the long-term adverse events reported in enzalutamide-treated CRPC patients from NCT02669771?
Are there combination therapies involving enzalutamide that improve survival in CRPC compared to monotherapy?